Table 1 Maternal and labour characteristics for women giving birth vaginally or by CD
Characteristic | Vaginal N = 900 (84.9%) | Caesarean N = 160 (15.1%) | Total N = 1060 (100%) |
|---|---|---|---|
Allocated treatment in active phase of labour | |||
Placebo | 449 (49.9) | 86 (53.8) | 535 (50.5) |
Oxytocin | 451 (50.1) | 74 (46.2) | 525 (49.5) |
Parity | |||
0 | 596 (66.2) | 136 (85.0) | 732 (69.1) |
1 | 192 (21.3) | 18 (11.2) | 210 (19.8) |
>1 | 112 (12.4) | 6 (3.8) | 118 (11.1) |
Indication for oxytocin | |||
Induced labour* | 561 (62.3) | 114 (71.2) | 675 (63.7) |
Prelabour rupture of membranes | 339 (37.7) | 46 (28.7) | 385 (36.3) |
Maternal pyrexia during labour** | |||
No | 821 (91.2) | 124 (77.5) | 945 (89.2) |
Yes | 79 (8.8) | 35 (21.9) | 114 (10.8) |
Previous CD | |||
No | 833 (92.6) | 144 (90.0) | 977 (92.2) |
Yes | 67 (7.4) | 16 (10.0) | 83 (7.8) |
Missing | 0 (0.0) | 1 (0.6) | 1 (0.1) |
Maternal height (cm) | |||
Mean (SD) | 170.3 (39.7) | 165.7 (6.8) | 169.6 (36.7) |
Maternal pre-pregnancy weight (kg) | |||
Mean (SD) | 76.7 (47.0) | 74.6 (17.2) | 76.3 (43.8) |
Maternal pre-pregnancy BMI (kg/m2) | |||
Mean (SD) | 28.4 (46.2) | 27.1 (5.9) | 28.2 (42.6) |
Smoking during pregnancy | |||
Missing | 18 (2.0) | 2 (1.2) | 20 (1.9) |
No | 742 (82.4) | 141 (88.1) | 883 (83.3) |
Yes | 140 (15.6) | 17 (10.6) | 157 (14.8) |
Marital status | |||
co-habiting | 474 (52.7) | 96 (60.0) | 570 (53.8) |
married | 334 (37.1) | 49 (30.6) | 383 (36.1) |
single | 80 (8.9) | 13 (8.1) | 93 (8.8) |
Missing N (%) | 12 (1.3) | 2 (1.2) | 14 (1.3) |
Estimated birthweight (g) | |||
Mean (SD) | 3548 (395.6) | 3724 (352.7) | 3575 (394.4) |
Missing N (%) | 72 (8) | 10 (6) | 978 (92) |
Gestational diabetes | |||
No | 820 (91.1) | 140 (87.5) | 960 (90.6) |
Yes | 80 (8.9) | 20 (12.5) | 100 (9.4) |
Hypertension during pregnancy*** | |||
No | 813 (90.3) | 149 (93.1) | 962 (90.8) |
Yes | 87 (9.7) | 11 (6.9) | 98 (9.2) |
Preeclampsia | |||
No | 846 (94.0) | 144 (90.0) | 990 (93.4) |
Yes | 54 (6.0) | 16 (10.0) | 70 (6.6) |
Inflammatory bowel disease | |||
No | 869 (96.6) | 153 (95.6) | 1,022 (96.4) |
Yes | 31 (3.4) | 7 (4.4) | 38 (3.6) |
Small for gestational age21 | |||
No | 878 (97.6) | 159 (99.4) | 1,037 (97.8) |
Yes | 22 (2.4) | 1 (0.6) | 23 (2.2) |
Autoimmune disease **** | |||
No | 883 (98.1) | 157 (98.1) | 1,040 (98.1) |
Yes | 17 (1.9) | 3 (1.9) | 20 (1.9) |
Use of anti-depressive medication at term | |||
No | 879 (97.7) | 152 (95.0) | 1,031 (97.3) |
Yes | 21 (2.3) | 8 (5.0) | 29 (2.7) |
Length of gestation at birth (days) | |||
Mean (SD) | 281.0 (9.7) | 284.3 (8.9) | 281.5 (9.7) |
Cervical ripening: oral prostaglandins | |||
No | 546 (60.7) | 70 (43.8) | 616 (58.1) |
Yes | 353 (39.2) | 90 (56.2) | 443 (41.8) |
Missing | 1 (0.1) | 0 (0.0) | 1 (0.1) |
Total dose of oral prostaglandins given (µg) | |||
Mean (SD) | 201.6 (141.6) | 220.0 (147.7) | 205.3 (142.9) |
Missing N (%) | 41 (12) | 10 (11) | |
Cervical ripening: cervical ripening catheter | |||
No | 782 (86.9) | 135 (84.4) | 917 (86.5) |
Yes | 116 (12.9) | 25 (15.6) | 141 (13.3) |
Missing | 2 (0.2) | 0 (0.0) | 2 (0.2) |
Cervical dilatation at oxytocin stimulation (cm) | |||
Mean (SD) | 2.5 (1.0) | 2.6 (1.0) | 2.6 (1.0) |
Missing N (%) | 14 (2) | 0 (0) | 14 (1) |
Cervical dilatation at randomisation (cm) | |||
Mean (SD) | 7.2 (1.4) | 6.6 (1.0) | 7.1 (1.4) |
Missing N (%) | 1 (0.1) | 0 (0) | 1 (0.09) |
Epidural use | |||
No | 369 (41.0) | 19 (11.9) | 388 (36.6) |
Yes | 531 (59.0) | 141 (88.1) | 672 (63.4) |
Volume of oxytocin (IU) ***** | |||
Median (IQR) | 1.7 (0.80–3.5) | 2.8 (1.4–4.4) | 1.8 (0.9–3.7) |
Missing N (%) | 81 (2) | 21 (13) | 102 (10) |
Maximum dose of oxytocin (mIU/min) ***** | |||
Mean (SD) | 13.4 (6.7) | 15.8 (7.35) | 13.8 (6.9) |
Missing N (%) | 566 (63) | 96 (60) | 662 (62) |
Fetal sex | |||
Girl | 441 (49.0) | 54 (33.8) | 495 (46.7) |
Boy | 459 (51.0) | 106 (66.2) | 565 (53.3) |